Tryptophan degradation is an immune escape strategy shared by many tumors. However, cancer cells' compensatory mechanisms remain unclear. We demonstrate here that a shortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) resulted in ATF4-dependent up-regulation of several amino acid transporters, including SLC1A5 and its truncated isoforms, which in turn enhanced tryptophan and glutamine uptake. Importantly, SLC1A5 failed to be up-regulated in resting human T cells kept under low tryptophan conditions, but was enhanced upon cognate antigen T cell receptor engagement. Our results highlight key differences in the ability of tumor and T cells to adapt to tryptophan starvation and provide important insights into the poor prognosis of tumors co-expressing IDO and SLC1A5.
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Introduction
Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are ratelimiting enzymes of the kynurenine pathway, which converts the essential amino acid (EAA) tryptophan to kynurenine. IDO-mediated tryptophan degradation, long recognized as an antimicrobial resistance mechanism, has now been firmly established as a key metabolic regulator of the immune response in a number of settings, including maternal/fetal interface, autoimmunity and cancer. An increasing number of studies have demonstrated that tryptophan catabolism is an important mechanism of immune escape exploited by IDO-and TDO-expressing tumors. Many human cancers constitutively express IDO (1, 2) and TDO (3, 4) , and acquisition of these tryptophan-degrading enzymes by immunogenic tumors prevents their rejection by tumor-specific T cells (1, 3) .
Furthermore, high IDO expression correlates with poor clinical prognosis in several human cancers (5) and plays an immunosuppressive role in the context of immunotherapies (6) .
Starvation of cells from tryptophan and other amino acids is sensed through the general control nonderepressible protein 2 (GCN2) kinase pathway, which is activated in response to accumulation of uncharged tRNA. Upon activation, GCN2 phosphorylates the translation initiation factor eIF2α, which promotes translation of the master regulator of the integrated stress response, activating transcription factor 4 (ATF4) (7) . ATF4 regulates transcription of a spectrum of genes required for amino acid synthesis and import, redox balance and angiogenesis (8, 9) .
While it is known that in T cells, IDO-mediated tryptophan depletion induces a GCN2-dependent proliferative arrest (10) , inhibiting the G1-to-S phase transition (11, 12) (11, 12) . These results have led to the demonstration that overexpression of tryptophan-degrading enzymes IDO and TDO in tumor cells results in the up-regulation of several amino acid transporters, and in particular of SLC1A5 -a sodium-dependent high-affinity glutamine transporter of the solute carrier family (SLC) 1 (13, 14) , which is overexpressed in several human cancers.
In this study, we establish a causative relationship between IDO-mediated tryptophan degradation and SLC1A5 up-regulation, and characterize the dichotomy of this phenomenon in tumor cells and T lymphocytes. 
Analysis of mRNA expression in primary human tumors
Expression of mRNA measured by RNA sequencing was downloaded from the TCGA data portal for LIHC (n=374), OV (n=309), GBM (n=169), LGG (n=534), UCEC (n=177), ACC (n=79), CESC (n=306), BRCA (n=1102), and KIRC (n=534), and the Spearman's rank correlation coefficient was calculated between the expressions of SLC1A5 and WARS, TDO2, IDO1, and ATF4 for each tumor type. Additionally, clinical data was downloaded for the LGG samples, and Kaplan-Meier curves comparing survival of patients with low and high expression of SLC1A5, IDO1, and the combinations thereof were made. Statistical analysis was performed using log-rank test.
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad, San Diego, CA).
Unpaired, two-tailed Student's t-test was used to determine statistical significance, unless indicated otherwise. The threshold for rejection of the null hypothesis was p<0.05.
Research. several genes that were also up-regulated in IFNγ HeLa cells (Fig. 1A) . Such shared genetic signature between IDO + HeLa and IFNγ HeLa cells was more evident at 72h rather than at 48h (Fig. 1B) , which could be accounted for by differences in the kinetics required by IDO + HeLa cells to degrade tryptophan contained in the culture medium. At 72h, this shared transcriptional signature included the expression of genes involved in the regulation of cellular redox signaling and apoptosis (such as TXNIP (15)), t-RNA amino acylation, glutamine/glutamate and monosaccharide metabolism, and amino acid and carboxylic acid biosynthesis and transport, among other functions (Fig. 1A) . The most abundantly upregulated gene involved in t-RNA amino acylation was tryptophanyl-tRNA synthetase (WARS), while the most abundantly up-regulated genes associated with amino acid transport were SLC7A11 (cystine/glutamate exchanger), SLC1A4 (glutamate/neutral amino acid transporter), SLC1A5 (glutamine/neutral amino acid transporter) and, to a lesser extent, SLC6A9 (glycine neurotransmitter transporter) ( Fig. 1A and B) . Other major amino acid transporters, including CD98 heavy chain (SLC3A2) and LAT1 (SLC7A5) showed a less pronounced differential expression in HeLa cells expressing IDO (Fig. 1B) . Notably, out of the top four up-regulated SLC genes, SLC1A5 was the only transporter associated with EAA transport (16) and tryptophan transport network, as determined using the MetaCore pathway analysis software (Fig. S1B) .
Further analysis demonstrated that, in addition to the full-length SLC1A5 transcript, hereafter referred to as SLC1A5 long (SLC1A5(L)), there were truncated splice variants of SLC1A5 -SLC1A5 middle (SLC1A5(M)) and SLC1A5 short (SLC1A5(S)) (Fig. S1C) . We (Fig. 1C) . In agreement with the RNA-seq data, Real-Time PCR analysis of transcripts associated with SLC7A11 and SLC1A4 confirmed their up-regulation in IDO-and TDO-expressing HeLa cells (Fig. 1C) .
Next, we assessed SLC1A5 protein expression in tumor cells exhibiting IDO or TDO activity using an antibody specific for the N-terminus of the full length SLC1A5, which is expected to detect SLC1A5(L) but not the other isoforms. SLC1A5 expression levels increased substantially in tumor cells treated with IFNγ and those transduced with IDO or TDO (Fig. 1D) .
To validate that tumor cells overexpressing SLC1A5 are able to up-regulate their amino acid uptake, we overexpressed SLC1A5(L) and its most truncated isoform, SLC1A5(S), in HeLa cells. Since SLC1A5 has been reported to have high affinity for glutamine (13, 14, 17) , we first examined the capacity of transduced cells to transport radiolabeled Fig. 2A) . Notably, glutamine uptake capacity was also increased in tumor cells overexpressing SLC1A5(S) (Fig. 2A) . Consistently with the reported Na (18, 19) reduced glutamine uptake in a dose-dependent manner ( Fig. 2A) .
Next, we assessed the action of SLC1A5 on radiolabeled tryptophan (
Overexpression of SLC1A5(L), and particularly of SLC1A5(S) in HeLa cells, improved their tryptophan uptake capacity (Fig. 2B) . Conversely, radiolabeled tryptophan transport was reduced in the presence of SLC1A5 pharmacological inhibitor BenSer (Fig. 2C) . In line with these findings, BenSer treatment also reduced mTOR activation in HeLa cells (Fig. S2A) . Furthermore, SLC1A5 knockdown resulted in a significant impairment of HeLa cell proliferation under amino acid sufficient conditions ( Fig. S2B and C) . This effect was enhanced even further following tryptophan withdrawal (Fig. S2C) .
Although not reported to transport tryptophan directly (13, 17) , SLC1A5 has been proposed to facilitate the activity of the dominant neutral amino acid transporter LAT1 (SLC7A5) (20) through bidirectional transport (16) . Consistent with this model, we found that tryptophan uptake in HeLa cells is heavily dependent on LAT1 activity, as evidenced by the abolished radiolabeled tryptophan transport into tumor cells lacking LAT1 ( Fig. S2D and E).
Collectively, these findings demonstrate for the first time the association between tryptophan catabolism and modulation of metabolic and amino acid transporter profiling in While AhR agonists had no effect on the levels of SLC1A5 expression ( expression, while this induction was less profound in the absence of leucine or isoleucine (Fig. 3D) . Glycine or serine deprivation, on the other hand, exerted no effect on SLC1A5 expression (Fig. 3D) . Interestingly, tryptophan depletion, in addition to up-regulation of SLC1A5, also increased expression of SLC7A11 and SLC1A4 (Fig. 4G) , demonstrating a more general effect of tryptophan catabolism on the amino acid transporter profiling.
Collectively, these findings show that SLC1A5 expression is regulated by amino acid availability and demonstrate its sensitivity to variation in the local tryptophan concentration.
SLC1A5 up-regulation in tryptophan-starved tumor cells is dependent on the ATF4 pathway
We next assessed the possible mechanisms that may account for the induction of SLC1A5 during tryptophan starvation. Amino acid depletion is sensed by the ATF4 pathway, which can be activated in response to increased levels of uncharged tRNA (7). We interrogated our RNA-seq data for changes in the expression of stress response genes in IDO + tumor cells, and observed a strong transcriptional signature associated with ATF4 pathway activation, as evidenced by the up-regulation of ATF4, ATF3, CHOP, GADD34, TRIB3 and HERPUD1 genes in IFNγ-treated WT and IDO1-transduced HeLa cells ( Fig. 4A and B) . In line with the reported role of ATF4 in autophagy regulation (21) , tumor cells exposed to tryptophan deprivation also exhibited increased autophagy levels, as determined by elevated LC3-II to LC3-I ratio (Fig. S4) .
To investigate whether ATF4 expression is differentially modulated by the absence of distinct amino acids, we measured ATF4 levels in WT HeLa cells cultured under various amino acid-deprived conditions. While ATF4 protein was almost undetectable in complete medium, its expression increased markedly in tumor cells cultured in the absence of tryptophan, glutamine, and, to a lesser extent, arginine and isoleucine (Fig. 4C) . Lack of glycine and serine, on the other hand, failed to activate ATF4 in HeLa cells (Fig. 4C) .
Furthermore, similarly to SLC1A5, ATF4 expression was induced by concentrations of tryptophan lower than 5μM, as ATF4 could not be detected after supplementing the culture medium with 10μM tryptophan (Fig. 4D) . We thus demonstrated that ATF4 expression in starved tumor cells mirrors that of SLC1A5.
To determine the role of the ATF4 pathway in regulation of SLC1A5 expression under tryptophan-deficient conditions, we knocked down ATF4 from HeLa cells using a lentiviral CRISPR construct (Table S1 ). In contrast to WT tumor cells, no SLC1A5 up-regulation could be detected in ATF4 knockdown tumor cells under culture conditions lacking tryptophan (Fig. 4E) . We confirmed these results using ATF4 shRNA knockdown strategy (data not shown). Furthermore, similarly to SLC1A5(L), ATF4 knockdown tumor cells failed to up-regulate transcription of truncated SLC1A5 isoforms following tryptophan withdrawal (Fig. 4F) , underscoring that SLC1A5 isoform induction in tryptophan-starved tumor cells is also controlled by the ATF4 pathway. Similarly, we showed that upregulation of SLC7A11 and SLC1A4 in tryptophan-depleted medium was abolished in ATF4 knockdown cells (Fig. 4G) .
Collectively, these findings demonstrate the role of ATF4 in modulating the changes in amino acid transporter profiling under culture conditions with reduced concentrations of tryptophan.
SLC1A5 expression in human T cells is unaffected by tryptophan starvation
Tryptophan degradation by IDO-expressing tumors is a common mechanism of immune escape, which inhibits effector T cells (1, 3) . We (12) and others (10, 11, 22) antibodies readily up-regulated SLC1A5 expression (Fig. 5A) , which is consistent with the increased metabolic demands of activated T cells (23) . In line with these results, pharmacological inhibition of SLC1A5 reduced mTOR activation in stimulated T cells (Fig. S5A) .
Surprisingly, in sharp contrast to the up-regulation of SLC1A5 observed in a panel of tumor cell lines maintained under identical conditions, resting CD4 + and CD8 + T cells failed to enhance SLC1A5 expression in response to tryptophan depletion ( Fig. 5A and B) .
Moreover, while incubation of T cells with αCD3/CD28 antibodies led to increased SLC1A5 expression, tryptophan depletion of αCD3/CD28-treated T cells failed to induce further up-regulation of SLC1A5, in the face of ATF4 activation (Fig. 5A) . Human T cells kept in tryptophan-depleted medium also failed to express the alternative SLC1A5 isoform (Fig. 5B) . Notably, although T cells increased the levels of SLC1A5 expression upon stimulation, this up-regulation was not sufficient to facilitate levels of tryptophan uptake comparable to those observed in tumor cells (Fig. S5B) .
Furthermore, in contrast to tumor cells, tryptophan-starved T cells also failed to up-regulate tryptophanyl-tRNA synthetase WARS, while its expression, similarly to that of SLC1A5, was enhanced upon T cell activation (Fig. S5C) . These findings highlight differential regulation of ATF4-dependent genes controlling compensatory mechanisms triggered by the shortage of tryptophan in tumor and T cells.
Up-regulation of SLC1A5 in αCD3/CD28-treated T cells is consistent with the increased metabolic demand of activated T cells for amino acids such as glutamine (24,25).
Research. significantly higher levels of SLC1A5 expression than the IDO negative EG7 GFP tumors (Fig. S6A) .
We then investigated whether the association between tryptophan catabolism and SLC1A5 expression can be observed in primary human tumor samples. In line with regulation of SLC1A5 expression by the ATF4 pathway, our in silico analysis of available RNA-seq data demonstrated that in a large proportion of human tumors, SLC1A5 positively correlates with ATF4 expression (Fig. 6A) . However, since ATF4 activation can occur in response to several stresses, including hypoxia/anoxia and nutrient deprivation (29), we assessed whether co-expression of SLC1A5 and ATF4 correlated with the up-regulation of genes more relevant to catabolism of tryptophan in particular, such as tryptophanyl-tRNA synthetase WARS, which we have previously shown to be up-regulated in IDO-expressing and tryptophan-starved HeLa cells (Fig. 1A, 1B and S5C) . The results of this analysis demonstrated a strong positive correlation between SLC1A5 and WARS expression in several tumors, particularly human liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, glioblastoma multiforme and brain lower grade glioma (Fig. 6A) .
Importantly, in these tumor types SLC1A5 also correlated significantly with the expression of one or both of the tryptophan-degrading enzyme-encoding genes IDO1 and TDO2 (Fig.   6A) , hence supporting our in vitro data describing the tryptophan shortage-induced SLC1A5 up-regulation in IDO + and TDO + tumor cell lines.
We next assessed the significance of SLC1A5 and IDO1 tumor expression for patient prognosis. We found that, in brain lower grade glioma, which exhibited a particularly strong positive correlation between SLC1A5 and IDO1 expression (Fig. 6A) , high expression of SLC1A5 was significantly associated with decreased patient survival (Hazard ratio=0.40526; log-rank test p-value=0.00006) (Fig. 6B) . We also observed a similar association between survival and high IDO1 expression in this tumor type (Hazard (Fig. 6D and S6B ).
These data highlight the clinical importance of IDO and SLC1A5 up-regulation by human tumors such as brain lower grade glioma, and suggest their potential use as prognostic biomarkers.
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on Up-regulation of SLC1A5 (and its splice variants), in addition to enhancing the uptake of glutamine, also improves tryptophan transport, which can be blocked by the SLC1A5-specific inhibitor BenSer (18, 19) or by deleting expression of LAT1 (SLC7A5) (20) 
which has been previously shown to be mediated by CARMA1 (25) 
